Search

Your search keyword '"Haag, Friedrich"' showing total 684 results
Start Over Author "Haag, Friedrich"
684 results on '"Haag, Friedrich"'

152. Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation

Author

Kobold, Sebastian, primary, Tams, Sinje, additional, Luetkens, Tim, additional, Cao, Yanran, additional, Sezer, Orhan, additional, Bartels, Britta Marlen, additional, Reinhard, Henrike, additional, Templin, Julia, additional, Bartels, Katrin, additional, Hildebrandt, York, additional, Lajmi, Nesrine, additional, Marx, Andreas, additional, Haag, Friedrich, additional, Bokemeyer, Carsten, additional, Kröger, Nicolaus, additional, and Atanackovic, Djordje, additional

Published
2011
Full Text
View/download PDF

153. Strong Antibody Responses Against a Unique Region of CT-Antigen SSX-2 Are Induced After Allogeneic Stem Cell Transplantation and Correlate with Clinical Remission In Patients with Multiple Myeloma

Author

Kobold, Sebastian, primary, Luetkens, Tim, additional, Cao, Yanran, additional, Eberhardt, Corinna, additional, Tams, Sinje, additional, Bartels, Britta Marlen, additional, Bartels, Katrin, additional, Meyer, Sabrina, additional, Haag, Friedrich, additional, Bokemeyer, Carsten, additional, Zander, Axel R., additional, Kröger, Nicolaus, additional, and Atanackovic, Djordje, additional

Published
2010
Full Text
View/download PDF

157. Quantitative Magnetic Resonance Imaging of Enzyme Activity on the Cell Surface: In Vitro and In Vivo Monitoring of ADP-Ribosyltransferase 2 on T Cells

Author

Bannas, Peter, primary, Graumann, Oliver, additional, Balcerak, Philipp, additional, Peldschus, Kersten, additional, Kaul, Michael Gerhard, additional, Hohenberg, Heinrich, additional, Haag, Friedrich, additional, Adam, Gerhard, additional, Ittrich, Harald, additional, and Koch-Nolte, Friedrich, additional

Published
2010
Full Text
View/download PDF

158. The family of toxin-related ecto-ADP-ribosyltransferases in humans and the mouse.

Author

Reche Gallardo, Pedro Antonio, Glowacki, Gustavo, Braren, Rickmer, Firner, Kathrin, Nissen, Marion, Kühl, Maren, Bazan, Fernando, Cetkovic-Cvrlje, Marina, Leiter, Edward, Haag, Friedrich, Koch-Nolte, Friedrich, Reche Gallardo, Pedro Antonio, Glowacki, Gustavo, Braren, Rickmer, Firner, Kathrin, Nissen, Marion, Kühl, Maren, Bazan, Fernando, Cetkovic-Cvrlje, Marina, Leiter, Edward, Haag, Friedrich, and Koch-Nolte, Friedrich

Abstract

ADP-ribosyltransferases including toxins secreted by Vibrio cholera, Pseudomonas aerurginosa, and other pathogenic bacteria inactivate the function of human target proteins by attaching ADP-ribose onto a critical amino acid residue. Cross-species polymerase chain reaction (PCR) and database mining identified the orthologs of these ADP-ribosylating toxins in humans and the mouse. The human genome contains four functional toxin-related ADP-ribosyltransferase genes (ARTs) and two related intron-containing pseudogenes; the mouse has six functional orthologs. The human and mouse ART genes map to chromosomal regions with conserved linkage synteny. The individual ART genes reveal highly restricted expression patterns, which are largely conserved in humans and the mouse. We confirmed the predicted extracellular location of the ART proteins by expressing recombinant ARTs in insect cells. Two human and four mouse ARTs contain the active site motif (R-S-EXE) typical of arginine-specific ADP-ribosyltransferases and exhibit the predicted enzyme activities. Two other human ARTs and their murine orthologues deviate in the active site motif and lack detectable enzyme activity. Conceivably, these ARTs may have acquired a new specificity or function. The position-sensitive iterative database search program PSI-BLAST connected the mammalian ARTs with most known bacterial ADP-ribosylating toxins. In contrast, no related open reading frames occur in the four completed genomes of lower eucaryotes (yeast, worm, fly, and mustard weed). Interestingly, these organisms also lack genes for ADP-ribosylhydrolases, the enzymes that reverse protein ADP-ribosylation. This suggests that the two enzyme families that catalyze reversible mono-ADP-ribosylation either were lost from the genomes of these nonchordata eucaryotes or were subject to horizontal gene transfer between kingdoms., Depto. de Inmunología, Oftalmología y ORL, Fac. de Medicina, TRUE, pub

Published
2002

159. An RT6a gene is transcribed and translated in lymphopenic diabetes-prone BB rats

Author

Heinz-Günter Thiele, Eugene S. Handler, Friedrich Haag Friedrich, Debra J. Waite, Dale L. Greiner, John P. Mordes, Laura Crisá, Thiruchandurai V. Rajan, Aldo A. Rossini, and Probir Sarkar

Subjects
Antigens, Differentiation, T-Lymphocyte, medicine.medical_specialty, Transcription, Genetic, medicine.drug_class, Endocrinology, Diabetes and Metabolism, T-Lymphocytes, Cell, Spleen, Biology, Monoclonal antibody, Polymerase Chain Reaction, Antigen, Internal medicine, Histocompatibility Antigens, Gene expression, Internal Medicine, medicine, Animals, Rats, Inbred BB, Lymph node, Regulation of gene expression, ADP Ribose Transferases, Messenger RNA, Membrane Glycoproteins, Brain, Molecular biology, Rats, medicine.anatomical_structure, Endocrinology, Diabetes Mellitus, Type 1, Liver, Organ Specificity, Protein Biosynthesis, RNA
Abstract

T-cells expressing the RT6 surface alloantigen appear to perform important immunoregulatory functions in the rat. Diabetes-prone BB rats lack circulating RT6 + T-cells and spontaneously develop autoimmune diabetes mellitus and thyroiditis. The coisogenic diabetes-resistant BB rat does circulate RT6 + T-cells and is free of disease. Transfusions leading to engraftment of RT6 + T-cells prevent both diabetes and thyroiditis in the diabetes-prone rat. To investigate the absence of this subset in the lymphopenic BB rat, we used both molecular and biochemical procedures and made the following observations: 1 ) an mRNA encoding RT6 protein is present in diabetes-prone spleen cells; 2 ) nucleotide sequencing of this transcript reveals an intact coding sequence for the RT6.1 alloantigen; 3 ) sensitive chemiluminescent assay of diabetes-prone lymph node cell detergent extracts shows that diabetes-prone RT6 mRNA is translated in vivo; 4 ) quantitatively, diabetes-prone lymph node cells express ≤ 10% of the RT6.1 protein found on similar numbers of diabetes-resistant BB cells; and 5 ) finally, we obtained evidence of an intact phosphatidylinositol linkage of the molecule to the cell surface and successfully immunoprecipitated the phosphatidylinositol-linked protein with DS4.23 monoclonal antibody, indicating that the RT6.1 antigen is correctly processed and folded in diabetes-prone lymph node cells. We conclude that the near total absence of RT6 + T-cells in the diabetes-prone BB rat is unlikely to be because of a defect in RT6 gene expression per se. Defects in RT6 gene regulation or other cellular defects leading to premature cell death in the T-cell lineage, alone or in combination, may instead be responsible.

Published
1993

160. Longitudinal and Functional Analysis of Spontaneous NY-ESO-1-Specific Antibody Responses in Multiple Myeloma Patients.

Author

Kobold, Sebastian, primary, Cao, Yanran, additional, Tams, Sinje, additional, Bartels, Britta Marlen, additional, Lütkens, Tim, additional, Pabst, Caroline, additional, Marx, Andreas, additional, Haag, Friedrich, additional, Bokemeyer, Carsten, additional, Kroeger, Nikolaus, additional, and Atanackovic, Djordje, additional

Published
2009
Full Text
View/download PDF

167. ADP-ribosyltransferases: plastic tools for inactivating protein and small molecular weight targets

Author

Reche Gallardo, Pedro Antonio, Koch-Nolte, Friedrich, Haag, Friedrich, Bazan, Fernando, Reche Gallardo, Pedro Antonio, Koch-Nolte, Friedrich, Haag, Friedrich, and Bazan, Fernando

Abstract

ADP-ribosyltransferases (ADPRTs) form an interesting class of enzymes with well-established roles as potent bacterial toxins and metabolic regulators. ADPRTs catalyze the transfer of the ADP-ribose moiety from NAD(+) onto specific substrates including proteins. ADP-ribosylation usually inactivates the function of the target. ADPRTs have become adapted to function in extra- and intracellular settings. Regulation of ADPRT activity can be mediated by ligand binding to associated regulatory domains, proteolytic cleavage, disulphide bond reduction, and association with other proteins. Crystallisation has revealed a conserved core set of elements that define an unusual minimal scaffold of the catalytic domain with remarkably plastic sequence requirements--only a single glutamic acid residue critical to catalytic activity is invariant. These inherent properties of ADPRTs suggest that the ADPRT catalytic fold is an attractive, malleable subject for protein design., Depto. de Inmunología, Oftalmología y ORL, Fac. de Medicina, TRUE, pub

Published
2001

172. Single domain antibodies that block a toxin-related T cell ecto-enzyme: cloning of fusion proteins that facilitate crystallization and that prolong the in-vivo half life

Author

Wesolowski, Janusz, primary, Burkert, Kristina, additional, Reyelt, Jan, additional, Schwarz, Nicole, additional, Haag, Friedrich, additional, Scheuplein, Felix, additional, Alzogaray, Vanina, additional, Goldbaum, Fernando A., additional, and Koch-Nolte, Friedrich, additional

Published
2007
Full Text
View/download PDF

175. Chemokine Receptor CXCR3 Mediates T Cell Recruitment and Tissue Injury in Nephrotoxic Nephritis in Mice

Author

Panzer, Ulf, primary, Steinmetz, Oliver M., additional, Paust, Hans-Joachim, additional, Meyer-Schwesinger, Catherine, additional, Peters, Anett, additional, Turner, Jan-Eric, additional, Zahner, Gunther, additional, Heymann, Felix, additional, Kurts, Christian, additional, Hopfer, Helmut, additional, Helmchen, Udo, additional, Haag, Friedrich, additional, Schneider, Andre[Combining Acute Accent], additional, and Stahl, Rolf A.K., additional

Published
2007
Full Text
View/download PDF

177. Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection.

Author

Bannas, Peter, Lenz, Alexander, Kunick, Valentin, Well, Lennart, Fumey, William, Rissiek, Björn, Haag, Friedrich, Schmid, Joanna, Schütze, Kerstin, Eichhoff, Anna, Trepel, Martin, Adam, Gerhard, Ittrich, Harald, and Koch-Nolte, Friedrich

Abstract

The utility of nanobodies and conventional antibodies for in vivo imaging is well known, but optimum dosing and timing schedules for one versus the other have not been established. We aimed to improve specific tumor imaging in vivo with nanobodies and conventional antibodies using near-infrared fluorescence (NIRF) imaging. We used ARTC2 expressed on lymphoma cells as a model target antigen. ARTC2-specific nanobody s+16a and conventional antibody Nika102 were labeled with NIRF-dye AF680. In vivo NIRF-imaging of ARTC2-positive and ARTC2-negative xenografts was performed over 24 h post-injection of 5, 10, 25, or 50 µg of each conjugate. Specific target-binding and tissue-penetration were verified by NIRF imaging ex vivo, flow cytometry and fluorescence microscopy. NIRF-imaging of s+16a680 in vivo revealed a six times faster tumor accumulation than of Nika102680. Using 50 µg of s+16a680 increased the specific signals of ARTC2-positive tumors without increasing background signals, allowing a tumor-to-background (T/B) ratio of 12.4 ± 4.2 within 6 h post-injection. Fifty micrograms of Nika102680 increased specific signals of ARTC2-positive tumors but also of ARTC2-negative tumors and background, thereby limiting the T/B ratio to 6.1 ± 2.0. Ten micrograms of Nika102680 only slightly reduced specific tumor signals but dramatically reduced background signals. Ex vivo analyses confirmed a faster and deeper tumor penetration with s+16a680. Using nanobody s+16a allowed same-day imaging with a high T/B ratio, whereas antibody Nika102 gave optimal imaging results only 24 h post injection. Nanobody s+16a required a high dose, whereas antibody Nika102 had the best T/B-ratio at a low dose. Therefore, timing and dosage should be addressed when comparing nanobodies and conventional antibodies for molecular imaging purposes. Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

178. Targeted Disruption of CD38 Accelerates Autoimmune Diabetes in NOD/Lt Mice by Enhancing Autoimmunity in an ADP-Ribosyltransferase 2-Dependent Fashion

Author

Chen, Jing, primary, Chen, Yi-Guang, additional, Reifsnyder, Peter C., additional, Schott, William H., additional, Lee, Chul-Ho, additional, Osborne, Melissa, additional, Scheuplein, Felix, additional, Haag, Friedrich, additional, Koch-Nolte, Friedrich, additional, Serreze, David V., additional, and Leiter, Edward H., additional

Published
2006
Full Text
View/download PDF

183. A panel of monoclonal antibodies recognizing GPI-anchored ADP-ribosyltransferase ART4, the carrier of the Dombrock blood group antigens

Author

Parusel, Ines, primary, Kahl, Sarah, additional, Braasch, Fenja, additional, Glowacki, Gustavo, additional, Halverson, Gregory R., additional, Reid, Marion E., additional, Schawalder, Alissa, additional, Ortolan, Erika, additional, Funaro, Ada, additional, Malavasi, Fabio, additional, Hardie, Debbie, additional, Halder, Sapna, additional, Buckley, Christopher D., additional, Haag, Friedrich, additional, and Koch-Nolte, Friedrich, additional

Published
2005
Full Text
View/download PDF

198. A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma

Author

Schieferdecker, Aneta, Oberle, Anna, Thiele, Benjamin, Hofmann, Fabian, Göthel, Markus, Miethe, Sebastian, Hust, Michael, Braig, Friederike, Voigt, Mareike, von Pein, Ute-Marie, Koch-Nolte, Friedrich, Haag, Friedrich, Alawi, Malik, Indenbirken, Daniela, Grundhoff, Adam, Bokemeyer, Carsten, Bacher, Ulrike, Kröger, Nicolaus, and Binder, Mascha

Abstract

Multiple myeloma (MM) is a hematological cancer for which immune-based treatments are currently in development. Many of these rely on the identification of highly disease-specific, strongly and stably expressed antigens. Here, we profiled the myeloma B-cell immunome both to explore its predictive role in the context of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and to identify novel immunotherapeutic targets. We used random peptide phage display, reverse immunization, and next-generation sequencing–assisted antibody phage display to establish a highly myeloma-specific epitope fingerprint targeted by B-cell responses of 18 patients in clinical remission. We found that allogeneic HSCT more efficiently allowed production of myeloma-specific antibodies compared with autologous HSCT and that a highly reactive epitope recognition signature correlated with superior response to treatment. Next, we performed myeloma cell surface screenings of phage-displayed patient transplant immunomes. Although some of the screenings yielded clear-cut surface binders, the majority of screenings did not, suggesting that many of the targeted antigens may in fact not be accessible to the B-cell immune system in untreated myeloma cells. This fit well with the identification of heat-shock proteins as a class of antigens that showed overall the broadest reactivity with myeloma patient sera after allogeneic HSCT and that may be significantly translocated to the cell surface upon treatment as a result of immunogenic cell death. Our data reveal a disease-specific epitope signature of MM that is predictive for response to treatment. Mining of transplant immunomes for strong myeloma surface binders may open up avenues for myeloma immunotherapy.

Published
2016
Full Text
View/download PDF

200. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia.

Author

Rissiek, Anne, Schulze, Christian, Bacher, Ulrike, Schieferdecker, Aneta, Thiele, Benjamin, Jacholkowski, Anita, Flammiger, Anna, Horn, Christiane, Haag, Friedrich, Tiegs, Gisa, Zirlik, Katja, Trepel, Martin, Tolosa, Eva, and Binder, Mascha

Abstract

Antitumor immunity in chronic lymphocytic leukemia (CLL) is hampered by highly dysfunctional T-cells. Although certain T-cell subsets have been reported to be of prognostic significance in this disease, their interplay is complex and it remains incompletely understood which of these subsets significantly drive CLL progression. Here, we determined immunological profiles of 24 circulating T-cell subsets from 79 untreated individuals by multiparametric flow cytometry. This screening cohort included healthy donors, patients with monoclonal B-cell lymphocytosis (MBL), Rai 0 CLL and advanced CLL. We applied multidimensional scaling analysis as rigorous and unbiased statistical tool to globally assess the composition of the circulating T-cell environment and to generate T-cell scores reflecting its integrity. These scores allowed clear distinction between advanced CLL and healthy controls, whereas both MBL and Rai 0 CLL showed intermediate scores mirroring the biological continuum of CLL and its precursor stages. T-cell stimulation and suppression assays as well as longitudinal T-cell profiling showed an increasingly suppressive regulatory function initiating at the MBL stage. Effector function was impaired only after transition to CLL and partially recovered after chemoimmunotherapy. In an independent validation cohort of 52 untreated CLL cases, aberrant T-cell profiles were significantly associated with shorter time to treatment independently of other prognostic parameters. Random forest modeling predicted regulatory T-cell, gamma/delta and NKT-cells, as well as exhaustion of the CD8+ subset as potential drivers of progression. Our data illustrate a pathological T-cell environment in MBL that evolves toward a more and more suppressive and prognostically relevant profile across the disease stages. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results